Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 12

of 'Chemotherapy for advanced exocrine pancreatic cancer'

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.
Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC
Br J Surg. 1994;81(6):882.
Forty-three patients with irresectable advanced pancreatic cancer were randomized to receive chemotherapy using a combination of 5-fluorouracil, Adriamycin and mitomycin or no chemotherapy. Groups were well matched with regard to age, extent of disease and performance status on entry. Chemotherapy was well tolerated and, although common, side-effects were usually mild. Psychological measurements based on the Hospital Anxiety and Depression score were made in 31 patients. These showed significantly less depression but not anxiety in the treated group immediately after randomization and following 2 months of chemotherapy. Median survival in the treated group was 33 (range 9-80) weeks compared with 15 (range 1-62) weeks in the untreated group (P<0.002). Chemotherapy should be considered in all patients presenting with advanced inoperable pancreatic cancer.
Gastrointestinal Unit, Western General Hospital, Edinburgh, UK.